Evidence map›Paper›PMID 40678298›Full record

ReviewCurrent health sciences journal

Recent Advances in the Etiology and Neural Pathways Underlying Attention-Deficit and Hyperactivity Disorder.

Monica Grigore, Marius Viorel Ionică, Liliana Pătru, Victor Gheorman, Aurel Popa Wagner

Abstract readReview
In one paragraph

Review in Current health sciences journal. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Monica GrigoreDoctoral School, University of Medicine and Pharmacy of Craiova, Romania.
Marius Viorel IonicăDoctoral School, University of Medicine and Pharmacy of Craiova, Romania.
Liliana PătruExperimental Research Center for Normal and Pathological Aging, University of Medicine and Pharmacy of Craiova, Romania.
Victor GheormanDepartment of Psychiatry, University of Medicine and Pharmacy of Craiova, Romania.
Aurel Popa WagnerDoctoral School, University of Medicine and Pharmacy of Craiova, Romania.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The prevalence of mental disorders is increasing across the European Union, with at least one in four individuals expected to experience a psychiatric condition at some point in their lifetime. Notably, men and women often present with distinct symptomatology. Among neuropsychiatric disorders, attention-deficit/hyperactivity disorder (ADHD) is the most common and functionally impairing condition in childhood, affecting approximately 5% of minors. Its persistence into adulthood is substantial, with prevalence estimates reaching up to 3% in adult populations. ADHD is characterized by dysregulated dopaminergic signaling, which disrupts reward processing and motivation. Additionally, disturbances in circadian rhythms contribute to sleep dysregulation and metabolic dysfunction, further exacerbating symptom severity. While both mechanisms have been well-documented, their interaction remains insufficiently explored, particularly regarding its implications for diagnosis and treatment optimization. Future research should systematically examine the interplay between dopaminergic and noradrenergic dysfunction and circadian disruptions in ADHD, particularly in relation to symptom expression and comorbid conditions. Experimental paradigms assessing reward processing may provide valuable insights into dopamine and norepinephrine system alterations, while chronotherapeutic interventions-such as light therapy, sleep regulation, and behavioral adjustments-hold promise as potential therapeutic strategies. By integrating perspectives from neurobiology, chronobiology, and psychopharmacology, a more refined and individualized approach to ADHD management can be developed. Advancing this understanding may not only enhance ADHD treatment strategies but also yield novel therapeutic avenues for addressing its frequently co-occurring conditions.

Indexed as

ADHD managementAttention-deficitdopaminehyperactivity disordernorepinephrine

Identifiers

PMID40678298
PMCPMC12264998

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.